Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer

被引：4

作者：

Kaur, Sumanpreet ^{[1
]}

Bhattacharyya, Rajasri ^{[1
]}

Banerjee, Dibyajyoti ^{[1
]}

Shukla, Jaya ^{[2
]}

机构：

[1] PGIMER, Dept Expt Med & Biotechnol, Chandigarh 160012, India

[2] PGIMER, Dept Nucl Med, Chandigarh 160012, India

来源：

INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY | 2021年 / 36卷 / 01期

关键词：

Tucatinib; Trastumab; Synergism; Breast cancer;

D O I：

10.1007/s12291-019-00863-8

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Synergism in action of tucatinib and trastumab is reported in breast cancer management. However, its molecular basis is yet to be determined. In this context we attempted to provide an explanation at the molecular level by performing in silico experimentation and coupling its result with already available published observations. Our study will provide basis for planning further experimental study for unravelling the truth.

引用

页码：124 / 125

页数：2

共 5 条

[1] Dual inhibition of HER2 in breast cancer treatment [J].

Gnant, Michael ;

Steger, Guenther G. .

LANCET, 2012, 379 (9816) :596-598

[2] Genomic alterations of ERBB receptors in cancer: clinical implications [J].

Mishra, Rosalin ;

Hanker, Ariella B. ;

Garrett, Joan T. .

ONCOTARGET, 2017, 8 (69) :114371-114392

[3] Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer [J].

Mukohara, Toru .

CANCER SCIENCE, 2011, 102 (01) :1-8

[4] HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance [J].

Pernas, Sonia ;

Tolaney, Sara M. .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11

[5] Targeting HER2 in other tumor types [J].

Scholl, S ;

Beuzeboc, P ;

Pouillart, P .

ANNALS OF ONCOLOGY, 2001, 12 :81-87

← 1 →